Efgartigimod, as the first FcRn antagonist, has been approved for the treatment of myasthenia gravis (MG) in the United States, Europe, Japan (8, 17), and China (https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230704155106142.html). Here, FCGRT is linked to myasthenia gravis.